Kyowa Kirin Announces Acceptance for Presentations at the European Academy of Dermatology and Venereology Congress 2023

Kyowa Kirin Co., Ltd. (TSE: 4151) announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product being studied in patients

Related Keywords

Berlin ,Germany ,Japan ,Tokyo ,United States ,America ,Ehsanollah Esfandiari ,Hirotaka Mano ,Kenji Kabashima ,Emma Guttman Yassky ,Asia Pacific ,Camilla Chong ,European Academy Of Dermatology ,Jolla Institute For Immunology ,A Global Specialty Pharmaceutical Company ,Kyowa Kirin Us Research ,Prnewswire Kyowa Kirin Co Ltd ,Amgen ,European Academy ,Poster Title ,Phd Date ,Kyowa Kirin ,Kyowa Kirin Collaborationon June ,Kyowa Kirinkyowa Kirin ,North America ,Kyowa ,Study ,Data ,